Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) delivers innovative drug delivery solutions through its proprietary ENHANZE® technology, transforming subcutaneous administration of biologics. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones.
Access timely press releases covering earnings reports, ENHANZE® licensing agreements, and oncology pipeline advancements. Our curated collection features updates on FDA submissions, collaboration expansions with global pharmaceutical leaders, and technology applications across autoimmune disorders and cancer treatments.
Key updates include partnership announcements with industry leaders, clinical trial progress for subcutaneous therapies, and financial performance insights. The resource serves investors tracking royalty revenue models and analysts monitoring competitive positioning in biopharmaceutical delivery systems.
Bookmark this page for direct access to verified corporate communications and objective reporting on Halozyme's mission to enhance treatment experiences through advanced drug delivery platforms. Regularly updated to reflect the company's latest achievements in patient-centric biotechnology innovation.
Halozyme Therapeutics reported robust financial results for Q4 and full year 2021, with total revenue hitting $443.3 million, a 66% increase Year-over-Year (YoY). Royalty revenue soared 130% YoY, driven mainly by the subcutaneous products DARZALEX® and Phesgo®. The company anticipates a further 50% growth in royalty revenue in 2022. Although Q4 revenue dropped to $102.0 million from $121.7 million in 2020, net income for the full year totaled $402.7 million, or $2.74 per share. Halozyme's guidance for 2022 projects revenues of $530-560 million, with a net income of $270-295 million.
Halozyme Therapeutics (NASDAQ: HALO) has announced it will host a webcast for its fourth quarter 2021 financial results on February 22, 2022, at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, following the release of financial results after market close. Halozyme emphasizes its innovative ENHANZE® technology, which has improved treatment times for over 500,000 patients globally across five products. The company partners with major biopharmaceutical companies, generating revenue through collaborations and royalties.
Halozyme Therapeutics (NASDAQ: HALO) has promoted Nicole LaBrosse to Chief Financial Officer (CFO), succeeding Elaine Sun, who is leaving for another opportunity. LaBrosse, with over 18 years of experience, joined Halozyme in 2015 and has held progressively responsible roles, including Vice President of Finance since 2020. CEO Helen Torley expressed confidence in LaBrosse's ability to support the company's growth. Halozyme aims to improve patient experiences through its ENHANZE® technology, which streamlines treatment delivery, impacting over 500,000 patients globally.
Halozyme Therapeutics (NASDAQ: HALO) has announced its financial guidance for 2022, projecting total revenue between $530 million and $560 million, a growth of 23-26% from 2021. Royalties from products utilizing ENHANZE technology are expected to reach $300 million, a 50% increase. Operating income is forecasted at $350 million to $380 million, with a margin exceeding 65%. Key initiatives include further product development and share repurchase plans totaling up to $250 million.
Halozyme Therapeutics (NASDAQ: HALO) announced that Dr. Helen Torley, CEO, will present virtually at the 40th Annual J.P. Morgan Health Care Conference on January 10, 2022, at 7:30 a.m. PT. The conference runs from January 10-13, 2022. Interested parties can access the presentation via the Investors section of Halozyme's website. Halozyme specializes in biopharmaceutical solutions, particularly its ENHANZE® technology, which enhances drug delivery efficiency and has reached over 500,000 patients globally.
Halozyme Therapeutics (NASDAQ: HALO) has appointed Mark Snyder as the new senior vice president, general counsel, chief compliance officer, and corporate secretary, effective January 3, 2022. Snyder succeeds Masaru Matsuda, who is leaving for another opportunity. With nearly 30 years of legal and business experience, Snyder previously worked at Qualcomm, leading litigation strategies and managing legal operations. His appointment aims to enhance Halozyme's growth and shareholder value, as stated by CEO Helen Torley.
Halozyme Therapeutics has initiated a new share repurchase program, authorizing up to $750 million in buybacks over the next three years. This includes an accelerated share repurchase (ASR) of $150 million, with plans to acquire $250 million worth of shares by the end of 2022, contingent on market conditions. The program reflects Halozyme's commitment to a balanced capital allocation strategy, leveraging strong cash generation to return capital to investors while supporting growth initiatives.
Halozyme Therapeutics announced that Janssen Biotech received FDA approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with Kyprolis (carfilzomib) and dexamethasone for adult patients with relapsed or refractory multiple myeloma. This marks the ninth indication for DARZALEX FASPRO. The approval is based on data from Janssen's PLEIADES Study, which achieved its primary endpoint of overall response rate. The product leverages Halozyme's ENHANZE technology, facilitating rapid treatment administration that may enhance patient experience.
Halozyme Therapeutics (NASDAQ: HALO) will participate in two upcoming investor conferences:
- 33rd Annual Piper Sandler Virtual Healthcare Conference on November 22, 2021, featuring Elaine Sun in an on-demand chat.
- Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, with Dr. Helen Torley representing the company in a virtual chat.
Presentations can be accessed via the investors section of Halozyme.com, with recordings available for six months.
Halozyme Therapeutics reported Q3 2021 financial results, with revenues reaching $115.8 million, up 77% year-over-year, driven by a 145% increase in royalty revenue. The company expects full-year royalty revenue to more than double from 2020. Operating income rose to $75.6 million from $40.3 million in Q3 2020. Q3 net income surged to $216.6 million, influenced by a $142.5 million tax benefit. Halozyme also repurchased 4.4 million shares for $189.7 million through Q3. Revenue guidance for 2021 is now set between $430 million and $445 million.